Details of Drug-Drug Interaction
| Drug General Information (ID: DDIHU7S1FT) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Deferiprone | Drug Info | Ferrous fumarate | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Chelating Agents | Iron Supplement | |||||||
| Structure | |||||||||
| Mechanism of Deferiprone-Ferrous fumarate Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Complex formation Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Deferiprone | Ferrous fumarate | |||||||
| Mechanism | Binds to polyvalent cations | Polyvalent cations | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Chelation | ||||||||
| Factor Description | Chelation is a direct drug interaction that usually involves the formation of dimers or trimers, resulting in larger complexes and poorer absorption. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | A minimum 4-hour interval is recommended between the administration of deferiprone and mineral supplements or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) or other polyvalent cations. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD. | ||||||||||||||||||